在2025年APAC精密肿瘤会议上,人工智能和多组学推动了癌症的检测和治疗。 AI and multi-omics advance cancer detection and treatment at APAC Precision Oncology Conference 2025.

2025年在香港举行的APAC精密肿瘤学会议强调,在癌症护理方面,人工智能和多种工程学在现实世界中取得了进步,其特点是下一代的MCED血液测试,如SPOT-MAS, 检测到75种癌症,敏感度高达78%,特殊度高达99%。 The APAC Precision Oncology Conference 2025 in Hong Kong highlighted real-world advances in AI and multi-omics for cancer care, featuring next-generation MCED blood tests like SPOT-MAS that detect up to 75 cancer types with 78% sensitivity and 99% specificity from a single blood draw. 研究人员介绍了新的生物标志,包括稳定的循环RNA,并强调大赦国际在将基因组学、遗传学和临床数据结合起来,通过分子肿瘤板指导个性化治疗方面的作用。 Researchers presented new biomarkers, including stable circular RNAs, and emphasized AI’s role in integrating genomic, epigenetic, and clinical data to guide personalized treatment through molecular tumor boards. 对分子残留疾病的ctDNA监测正在获得临床牵引,支持早期重复检测和治疗调整。 ctDNA monitoring for molecular residual disease is gaining clinical traction, supporting early recurrence detection and treatment adjustments. 活动强调了区域向可扩展的、由数据驱动的精确肿瘤学转变,以改善早期诊断和患者结果。 The event underscored a regional shift toward scalable, data-driven precision oncology improving early diagnosis and patient outcomes.